James J. Farrell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James J. Farrell has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Bryson William Katona
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
17 shared publications - Randall E. Brand
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
17 shared publications Aaron Grossberg
16 shared publications- Aimee L. Lucas
Division of Gastroenterology and Hepatology, Mount Sinai Morningside and Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY
16 shared publications Andrew Lowy
16 shared publications- Daniel A. Sussman
Division of Digestive Health and Liver Diseases, Miller School of Medicine, University of Miami, Miami, Florida
16 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Increased Prevalence of Pancreatic Cysts in Nonsecretor (Fut2-Null) Individuals under Pancreatic Surveillance
Background: Pancreatic surveillance commonly detects pancreatic cysts, most of which are presumed intraductal papillary mucinous neoplasms (IPMN). FUT2, the gene responsible for secretor status, has been implicated in IPMN development, although not with pancreatic cancer risk. Methods: We evaluated the association between inactivating variants in FUT2, FUT3, and ABO and pancreatic cysts in 1,865 patients in the multicenter Cancer of the Pancreas Screening (CAPS) cohort. Multivariable logistic regression was performed to estimate adjusted odds for presumed IPMN prevalence. A Johns Hopkins surgical cohort of 1,582 patients with IPMN, pancreatic ductal adenocarcinoma (PDAC), or carcinoma arising from IPMN was analyzed to examine trend in variant proportion by malignant progression. Results: In the CAPS cohort, older age [OR per year, 1.06 (1.05–1.07); P < 0.001], being FUT2 null [nonsecretors; OR, 1.66 (1.30–2.12); P < 0.001], non-O blood group [OR, 1.31 (1.06–1.62); P = 0.012], having familial-only versus genetic/familial risk [OR, 1.49 (1.20–1.85); P < 0.001], and participating site [OR, 2.20 (1.78–2.73); P < 0.001] were associated with having pancreatic cysts. There were no significant FUT2/ABO-presumed IPMN prevalence interactions. In the combined cohort, the proportion of FUT2-null patients with IPMN without carcinoma (by imaging or pathology) was 319 (27.4%) of 1,162, 57 (24.3% of 234) with IPMN and carcinoma, and 225 (22.5%) of 998 with PDAC alone (P = 0.009 for trend). Conclusions: IPMN is more prevalent in FUT2-null patients under pancreas surveillance, but the increased FUT2-null prevalence is not observed in patients with IPMN with carcinoma. Impact: Pancreatic cancer risk conferred by having IPMN may be lower in FUT2-null compared with FUT2-intact individuals.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Open AccessIncreased Prevalence of Pancreatic Cysts in Nonsecretor (Fut2-Null) Individuals under Pancreatic Surveillance
Background: Pancreatic surveillance commonly detects pancreatic cysts, most of which are presumed intraductal papillary mucinous neoplasms (IPMN). FUT2, the gene responsible for secretor status, has been implicated in IPMN development, although not with pancreatic cancer risk. Methods: We evaluated the association between inactivating variants in FUT2, FUT3, and ABO and pancreatic cysts in 1,865 patients in the multicenter Cancer of the Pancreas Screening (CAPS) cohort. Multivariable logistic regression was performed to estimate adjusted odds for presumed IPMN prevalence. A Johns Hopkins surgical cohort of 1,582 patients with IPMN, pancreatic ductal adenocarcinoma (PDAC), or carcinoma arising from IPMN was analyzed to examine trend in variant proportion by malignant progression. Results: In the CAPS cohort, older age [OR per year, 1.06 (1.05–1.07); P < 0.001], being FUT2 null [nonsecretors; OR, 1.66 (1.30–2.12); P < 0.001], non-O blood group [OR, 1.31 (1.06–1.62); P = 0.012], having familial-only versus genetic/familial risk [OR, 1.49 (1.20–1.85); P < 0.001], and participating site [OR, 2.20 (1.78–2.73); P < 0.001] were associated with having pancreatic cysts. There were no significant FUT2/ABO-presumed IPMN prevalence interactions. In the combined cohort, the proportion of FUT2-null patients with IPMN without carcinoma (by imaging or pathology) was 319 (27.4%) of 1,162, 57 (24.3% of 234) with IPMN and carcinoma, and 225 (22.5%) of 998 with PDAC alone (P = 0.009 for trend). Conclusions: IPMN is more prevalent in FUT2-null patients under pancreas surveillance, but the increased FUT2-null prevalence is not observed in patients with IPMN with carcinoma. Impact: Pancreatic cancer risk conferred by having IPMN may be lower in FUT2-null compared with FUT2-intact individuals.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 1: Comparison of rates of pathogenic variants and cancer history by sex
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 1: Comparison of rates of pathogenic variants and cancer history by sex
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 5: Consent and biosample collection rates amongst HRIs stratified by age
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 5: Consent and biosample collection rates amongst HRIs stratified by age
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 4: Consent and biosample collection rates amongst HRIs stratified by high-risk subgroup
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 3: Consent and biosample collection rates amongst HRIs stratified by sex
- Open Access
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location
- 5 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance
Supplementary Table 2: Comparison of baseline characteristics of HRIs by site location